1-25(oh)2-16-ene-23-yne-d3 and Leukemia--Myeloid

1-25(oh)2-16-ene-23-yne-d3 has been researched along with Leukemia--Myeloid* in 1 studies

Other Studies

1 other study(ies) available for 1-25(oh)2-16-ene-23-yne-d3 and Leukemia--Myeloid

Article	Year
Metabolism of the cell differentiating agent 1alpha,25(OH)2-16-ene-23-yne vitamin D3 by leukemic cells. The Journal of steroid biochemistry and molecular biology, 1996, Volume: 57, Issue:1-2 The metabolism of 1alpha,25(OH)2D3 and 1alpha,25(OH)2-l6-ene-23-yne-D3 is examined by in vitro incubation of the steroid hormones with WEHI-3 myeloid leukemia cells. Two experimental systems were used to evaluate the metabolism of each compound: (a) a double label incubation was performed to determine both the propensity for metabolism of each analog and the in vitro half-life of the analogs; and (b) separate single label incubations were performed to determine the metabolite profile derived from each of the analogs. The double label WEHI-3 cell incubation with 25 nM [23,24(3)H]1alpha,25(OH)2D3 and 25 nM [25(14)C]1alpha,25(OH)2-16-ene-23-yne-D3 produced a single comigrating metabolite of higher polarity from each of the parent compounds in a gradient HPLC chromatogram. The half-life of each analog determined from this in vitro incubation was 6.9 and 6.7 h for 1alpha,25(OH)2D3 and 1alpha,25(OH)2-16-ene-23-yne-D3, respectively. Individual incubations of 1alpha,25(OH)2D3 yielded a metabolite that comigrates with 1alpha,24,25(OH)2D3 standard in each of three independent HPLC separations. Individual incubations with [25(14)C]1alpha,25(OH)2-16-ene-23-yne-D3 generated multiple metabolites, which are resistant to degradation as evaluated by intermediate build-up, are of increasing polarity and do not comigrate with the 1alpha,24,25(OH)3D3 standard. From these studies it is determined that 1alpha,25(OH)2-l6-ene-23-yne-D3 is metabolized differently but not preferentially compared to 1,25(OH)2D3 in myelogenous leukemia cells. Topics: Animals; Antineoplastic Agents; Calcitriol; Cell Differentiation; Chromatography, High Pressure Liquid; Leukemia, Myeloid; Mice; Tumor Cells, Cultured	1996

Article

Year

Metabolism of the cell differentiating agent 1alpha,25(OH)2-16-ene-23-yne vitamin D3 by leukemic cells.

The Journal of steroid biochemistry and molecular biology, 1996, Volume: 57, Issue:1-2

The metabolism of 1alpha,25(OH)2D3 and 1alpha,25(OH)2-l6-ene-23-yne-D3 is examined by in vitro incubation of the steroid hormones with WEHI-3 myeloid leukemia cells. Two experimental systems were used to evaluate the metabolism of each compound: (a) a double label incubation was performed to determine both the propensity for metabolism of each analog and the in vitro half-life of the analogs; and (b) separate single label incubations were performed to determine the metabolite profile derived from each of the analogs. The double label WEHI-3 cell incubation with 25 nM [23,24(3)H]1alpha,25(OH)2D3 and 25 nM [25(14)C]1alpha,25(OH)2-16-ene-23-yne-D3 produced a single comigrating metabolite of higher polarity from each of the parent compounds in a gradient HPLC chromatogram. The half-life of each analog determined from this in vitro incubation was 6.9 and 6.7 h for 1alpha,25(OH)2D3 and 1alpha,25(OH)2-16-ene-23-yne-D3, respectively. Individual incubations of 1alpha,25(OH)2D3 yielded a metabolite that comigrates with 1alpha,24,25(OH)2D3 standard in each of three independent HPLC separations. Individual incubations with [25(14)C]1alpha,25(OH)2-16-ene-23-yne-D3 generated multiple metabolites, which are resistant to degradation as evaluated by intermediate build-up, are of increasing polarity and do not comigrate with the 1alpha,24,25(OH)3D3 standard. From these studies it is determined that 1alpha,25(OH)2-l6-ene-23-yne-D3 is metabolized differently but not preferentially compared to 1,25(OH)2D3 in myelogenous leukemia cells.

Topics: Animals; Antineoplastic Agents; Calcitriol; Cell Differentiation; Chromatography, High Pressure Liquid; Leukemia, Myeloid; Mice; Tumor Cells, Cultured

1996